Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04971226 · OUTCOME

Trough Plasma Concentrations.

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP · Source last updated 2026-08-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
ng/mL
Interval / dispersion
Full Range
Time frame
Week 48

What was measured

Trough plasma concentration will measure the concentration of asciminib in the blood immediately before the next dose is administered.

Analysis population: Pharmacokinetic analysis set (PAS): All participants to whom study treatment has been assigned by randomization to asciminib and that had a valid trough plasma concentration taken at week 48.

Groups in this outcome

Asciminib (All Asciminib )

Patients took asciminib 80 mg QD under fasting conditions on ongoing basis.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Asciminib (All Asciminib )107

Reported measurements

Source class 1
Values in ng/mL · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Asciminib (All Asciminib )161Not reported11.91010Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        11.9
        upper Limit
        1010
        value
        161
denoms
  1. counts
    1. group Id
      OG000
      value
      107
    units
    Participants
description
Trough plasma concentration will measure the concentration of asciminib in the blood immediately before the next dose is administered.
dispersion Type
Full Range
groups
  1. description
    Patients took asciminib 80 mg QD under fasting conditions on ongoing basis.
    id
    OG000
    title
    Asciminib (All Asciminib )
param Type
MEDIAN
population Description
Pharmacokinetic analysis set (PAS): All participants to whom study treatment has been assigned by randomization to asciminib and that had a valid trough plasma concentration taken at week 48.
reporting Status
POSTED
time Frame
Week 48
title
Trough Plasma Concentrations.
type
SECONDARY
unit Of Measure
ng/mL

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice